NIHR Birmingham Biomedical Research Centre (BRC)

Vials of chemicals

The NIHR Birmingham BRC brings together the expertise of University Hospitals Birmingham NHS Foundation Trust (UHB) and the University of Birmingham, both founder-members of BHP, and is one of 20 NHS-University partnerships across England that have been awarded funding through the National Institute for Health Research (NIHR).

Officially opened in April 2017, Birmingham’s BRC aims to use utting edge experimental medicine to accelerate access to, and adoption of, drugs, devices and diagnostics tests for patients living with chronic inflammatory diseases.

BRC funding supports researchers of the highest calibre to develop innovative research ideas that can attract investment from other funders, furthering the nation’s economic growth.

Chronic inflammatory diseases such as arthritis, colitis and liver diseases are increasingly common and a major cause of suffering and early death. In Birmingham, we have been researching the underlying processes behind these diseases for many years. We are working towards building a centre of excellence that will allow us to take scientific discoveries through into new treatments for patients with inflammatory and autoimmune joint, muscle, bowel and liver diseases.
Professor David Adams
Director of Birmingham BRC and BHP

NIHR Birmingham Biomedical Research Centre is building on the outstanding clinical research infrastructure in Birmingham to carry out studies in well-defined groups of patients with inflammatory disease in which we are:

  • Testing new treatments that switch off or re-calibrate the overactive immune system that underpins these diseases
  • Developing new biomarkers that will allow us to select the best new treatment for each patient
  • Exploring the disease processes that drive these conditions, focusing on mechanisms that are shared between different conditions